Satellos Bioscience Inc. Common Stock (MSLE) Stock Price
MSLEStock
$6.46−6.00%52W
Market Cap$137.06M
P/E—
PEG Ratio—
Div yield—
Beta1.57
MSLE Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-17.68%
Price vs S&P 500 (4W)-27.68%
VGM Score49.15
MSLE Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.57 | -$0.56 | +2.18%(+$0.01) | |
| Q1 2026 | -$0.59 | -$0.53 | +10.17%(+$0.06) | |
| Q4 2025 | -$0.06 | -$0.50 | -733.33%(-$0.44) |
MSLE Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.20
4.27
4.27
4.27
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
MSLESatellos Bioscience Inc. Common Stock | — | — | C | — | — | — | — | $6.46 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Satellos Bioscience Inc. Common Stock
Satellos Bioscience is a regenerative medicine company developing novel therapeutics to stimulate and restore muscle function in severe neuromuscular disorders. The company's lead program is an oral therapeutic for Duchenne muscular dystrophy that addresses dysregulation identified as a key driver of disease progression. Satellos' approach targets the root cause of muscle degeneration rather than symptomatic relief, positioning the therapy as a potential disease-modifying treatment.